Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris Pharmaceuticals has reported that the US Patent Office has issued the first patent covering a broad class of compounds that activate the enzyme SIRT1.
Subscribe to our email newsletter
Several compounds or new chemical entities (NCEs) from this class lower glucose and improve insulin sensitivity in preclinical models of type 2 diabetes. The patent covers the first NCE that Sirtris plans to take into a human clinical safety trial in the first half of 2008.
Karl Normington, senior director of intellectual property at Sirtris, said: “Sirtris has a strong intellectual property program with over 180 patent applications for broad coverage of sirtuin activators, including composition of matter, formulations, and methods of treatment claims.”